about
Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back PainStudy of COV795 in Subjects With Osteoarthritis or Chronic Low Back PainRandomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsEfficacy and Safety of Trichuris Suis Ova (TSO) as Compared to PlaceboA Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back PainStudy Investigating the Impact Burden of Nocturia Using the Nocturia Impact DiarySafety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer PainA Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 YearsA Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of StatinsA Multicenter Study of NB-001 in the Treatment of Recurrent Herpes LabialisA 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of FesoterodineSofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus InfectionD-Ribose for Fatigue in Subjects With FibromyalgiaOpioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)Smoking Cessation Study In Healthy Adolescent SmokersStudy to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period oStudy of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled GoutA Study to Assess Efficacy and Safety of GLPG1972/S201086 in Patients With Knee OsteoarthritisA Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With ConstipationTrial To Evaluate PF-06730512 In Adults With Primary Focal Segmental GlomerulosclerosisLot-to-lot Consistency of Sci-B-Vac™ in AdultsImmunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.A Clinical Study to Test Efficacy and Safety of CNTX-4975-05 in Patients With Osteoarthritis Knee PainStudy to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM AdministrationStudy to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy InfantsSaroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic SteatohepatitisDextromethorphan Pediatric Acute Cough StudyEfficacy and Safety Study of Apremilast to Treat Active Ulcerative ColitisA Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking CessationA Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder
P6153
Q61955394-D2C08E33-5751-4FB5-B7C8-45991090275CQ61967058-E7DD2757-DCE1-47CA-9733-D4A3AC23AC05Q61967262-E3569F81-A93D-4798-BD43-1D08769989D7Q61975472-E5B136A4-5156-434C-9070-2D4265AAE189Q63315686-3FCAE4DC-B780-46AD-8823-DCBF08F397F2Q63316601-7E1112EC-06D6-498D-9672-642D604EC45FQ63319575-B6C30EB2-B274-404E-B30F-62C2EE2070D7Q63320552-F3DC4244-2EB2-4931-B9AC-349764FAADFDQ63334100-EB74D502-EF73-45B1-A0E9-65BE306AA080Q63334933-B5306C56-ADFE-4FDC-A693-4867DB725ECBQ63336258-1C382361-6084-44D5-B12A-5E7B89BDEAD0Q63337614-DC36CB03-9BD8-4D77-B2C3-2850940E12EAQ63338113-BDE0C585-BD09-49DD-BDD6-C7DD66E59406Q63338127-6864C911-1BFA-4D5E-B1DC-6CB7AF7FA3ADQ63338406-D8321812-CBD0-425A-91DD-F06DFC198990Q63338735-F0F60653-6A07-453C-AEF5-C79B0306D3AFQ63338927-76D52D2F-2220-48FB-8A43-A9967E2539ACQ63340267-C17929BD-E670-4648-8E81-7E4600BE7B7AQ63394165-B986E02A-B6BC-4406-9F0F-918E530F0724Q63394667-4A55DD8E-500B-4E29-877A-6AD72C23A585Q63397019-405CF856-604E-4B39-A9E1-DE99107A0FDFQ63401213-AA479AFA-14D8-45E5-B2AD-D5F8D3DF7125Q63403502-45544B2C-F354-4B5C-BEA5-D8F4BA9B39FAQ63404357-5A4C4A60-3115-4F30-9C28-7FAFF2A3A5CCQ63404649-8306BB46-3C28-49E2-9BE6-2E48E37BEB7CQ63534576-48FAD048-5978-4773-A685-8D9346EBF5B9Q63571781-0CDD0673-04EA-47F1-9C88-845A4AE2A1C9Q63573776-01FE8BB0-3778-48DD-99F3-D42207277D3AQ64151455-71D8101F-0094-4C61-B26D-AB99F13F2EB1Q64172791-C537DF6E-DEAF-48F5-BCAD-1F4C204D72B4Q64172993-E79FFF05-2602-4E91-B56F-B1D866A76D0BQ64187795-48CE29ED-7B44-412D-8F09-4616E901C4BB
P6153
description
facility in DeLand, United States
@en
name
Avail Clinical Research
@en
type
label
Avail Clinical Research
@en
prefLabel
Avail Clinical Research
@en
P131
P2427
grid.476967.d
P31
P571
1998-01-01T00:00:00Z
P625
Point (-81.315024 29.04468)